Newsbytes
  • India
  • Business
  • World
  • Politics
  • Sports
  • Science
  • Entertainment
  • Auto
  • Lifestyle
  • Inspirational
  • Career
  • Bengaluru
  • Delhi
  • Mumbai
  • Videos
  • Phone Reviews
  • Find Cricket Statistics
Hindi
More
Newsbytes
Hindi
Newsbytes
User Placeholder

Hi,

Logout


India
Business
World
Politics
Sports
Science
Entertainment
Auto
Lifestyle
Inspirational
Career
Bengaluru
Delhi
Mumbai
Videos
Phone Reviews
Find Cricket Statistics

More Links
  • Videos

Download Android App

Follow us on
  • Facebook
  • Twitter
  • Linkedin
  • Youtube
 
Home / News / Science News / SII says Covishield 'safe' after trial participant sends legal notice
  • Science

    SII says Covishield 'safe' after trial participant sends legal notice

    Siddhant Pandey
    Written by
    Siddhant Pandey
    Twitter
    Last updated on Dec 01, 2020, 02:53 pm
    SII says Covishield 'safe' after trial participant sends legal notice
  • The Serum Institute of India (SII) on Tuesday said that its COVID-19 vaccine candidate was "safe and immunogenic," in response to allegations that a trial participant developed serious side-effects after being administered the dose.

    The Pune-based institute also said that it has served the trial participant, a 40-year-old man, a legal notice for "maligning" its reputation.

    Here are more details.

  • In this article
    Trial participant's condition 'no way induced by vaccine' Participant claimed he faced virtual neurological breakdown; demanded Rs. 5cr Earlier, SII said it would seek Rs. 100cr in damages SII's move 'blatant attempt at intimidation,' say experts Covishield undergoing Phase III trials
  • Details

    Trial participant's condition 'no way induced by vaccine'

    Trial participant's condition 'no way induced by vaccine'
  • The SII said that the trial participant's side-effects were in "no way induced by the vaccine."

    According to ANI, the institute said, "All regulatory, ethical processes and guidelines were followed by the company. The principal investigator DSMB (Data and Safety Monitoring Board) and ethics committee stated it was a non-related issue to vaccine trial."

    It said the man has been served a legal notice.

  • Side-effects

    Participant claimed he faced virtual neurological breakdown; demanded Rs. 5cr

    Participant claimed he faced virtual neurological breakdown; demanded Rs. 5cr
  • The 40-year-old had participated in the vaccine's Phase III trials conducted at the SRIHER site in Chennai.

    In a legal notice to the SII and others, he claimed that the side-effects he faced included a virtual neurological breakdown and impairment of cognitive functions.

    He sought financial compensation of Rs. 5 crore and demanded that the vaccine's testing, manufacturing, and distribution be halted immediately.

  • Notice

    Earlier, SII said it would seek Rs. 100cr in damages

  • The SII had said Sunday that the allegations were "malicious and misconceived" and seemed to have an oblique pecuniary motive.

    "The volunteer is falsely laying the blame for his medical problems on the vaccine trial," it had said, adding that he had been informed that his complications were independent of the vaccine trial.

    The institute said it will seek Rs. 100 crore in damages.

  • Experts

    SII's move 'blatant attempt at intimidation,' say experts

    SII's move 'blatant attempt at intimidation,' say experts
  • Bioethics expert Professor Anant Bhan said on Twitter that the SII's decision to counter-sue was a "bad move."

    "If there is an issue about the serious adverse event, better to engage with the participant to understand their concerns," Bhan said.

    The All India Drug Action Network (AIDAN) has also said, "This is a blatant attempt of intimidation," demanding transparency from drug regulators.

  • Vaccine

    Covishield undergoing Phase III trials

    Covishield undergoing Phase III trials
  • Covishield has been developed at SII with a master seed from pharma giant AstraZeneca and Oxford University. The potential vaccine is currently undergoing Phase III trials.

    It has shown 90% and 62% efficacy in two dosing regimens, reflecting an average efficacy of 70%.

    The first batch of 100 million doses—for priority groups—is expected by January, while broader access is likely by April.

  • Twitter
  • Oxford University
  • ANI
  • Coronavirus
  • Serum Institute of India
  •  
Latest News
  • IPL 2021: Rohit Sharma set to play his 200th innings
    IPL 2021: Rohit Sharma set to play his 200th innings
    Sports
  • IPL 2021, RCB thrash RR to remain unbeaten: Records broken
    IPL 2021, RCB thrash RR to remain unbeaten: Records broken
    Sports
  • IPL 2021: RCB restrict RR to 177/9
    IPL 2021: RCB restrict RR to 177/9
    Sports
  • Hackers leak Apple iMac, unreleased MacBook schematics, demand $50 million
    Hackers leak Apple iMac, unreleased MacBook schematics, demand $50 million
    Science
  • West Bengal election: TMC worker shot at; party blames CRPF
    West Bengal election: TMC worker shot at; party blames CRPF
    Politics
Related Timelines
  • Severe side-effects after COVID-19 vaccine: What are your legal options?
    Severe side-effects after COVID-19 vaccine: What are your legal options?
    India
  • SII, Bharat Biotech ensure 'smooth roll out' of vaccines globally
    SII, Bharat Biotech ensure 'smooth roll out' of vaccines globally
    India
  • SII's Covishield, Bharat Biotech's COVAXIN granted emergency approval, says DCGI
    SII's Covishield, Bharat Biotech's COVAXIN granted emergency approval, says DCGI
    India
  • Coronavirus: 'Davai bhi, kadaai bhi,' Modi calls for sustained caution
    Coronavirus: 'Davai bhi, kadaai bhi,' Modi calls for sustained caution
    India
Trending Topics
Microsoft Samsung Amazon Apple OnePlus Mobiles Android TV Smart TV Latest Gadget Launch MediaTek Dimensity 1000+ COVAXIN Latest Tech News Upcoming Mobile Phones
Next News Article
Share
Cancel

Want to share it with your friends too?

Facebook Whatsapp Twitter Linkedin
Copied

Love Science news?

Subscribe to stay updated.

Science Thumbnail
India News Business News World News Politics News Sports News Science News Entertainment News Auto News Lifestyle News Inspirational News
Career News Bengaluru News Delhi News Mumbai News Bharti Airtel Mukesh Ambani Microsoft Indian Premier League Samsung Virat Kohli
Rohit Sharma Cricket News YouTube Hollywood News WhatsApp Netflix Bollywood News ISRO Yoga Honda
Batman Football News BMW Vaccine Reliance Jio OPPO Amazon Food News, Healthy Recipes Apple Royal Challengers Bangalore
Toyota Fashion Tips Mercedes Isha Ambani India Vs England Cricket OnePlus Mobiles Android TV Smart TV Marvel Comics Avengers
Neha Kakkar X-Men TATA Eoin Morgan
About Us Privacy Policy Terms & Conditions Contact Us News Reviews News Archive Topics Archive Find Cricket Statistics
Follow us on
Facebook Twitter Linkedin Youtube
All rights reserved © NewsBytes 2021